PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1

被引:39
|
作者
Chen, Zhiqiang [1 ,2 ]
Gao, Wen [3 ]
Pu, Liyong [1 ,2 ]
Zhang, Long [1 ,2 ]
Han, Guoyong [1 ,2 ]
Zuo, Xueliang [1 ,2 ]
Zhang, Yao [1 ,2 ]
Li, Xiangcheng [1 ,2 ]
Shen, Hongbing [4 ,5 ]
Wu, Jindao [1 ,2 ,4 ]
Wang, Xuehao [1 ,2 ]
机构
[1] Nanjing Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
[2] Natl Hlth & Family Planning Commiss, Key Lab Living Donor Liver Transplantat, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
[4] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China
[5] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Dept Epidemiol & Biostat,Sch Publ Hlth, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
DNA METHYLATION; EXPRESSION; DIFFERENTIATION; PATHWAY; FAMILY; GENES;
D O I
10.1002/hep.29890
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. PRDI-BF1 and RIZ homology domain containing 8 (PRDM8) is a key regulator in neural development and testis steroidogenesis; however, its role in liver carcinogenesis remains to be investigated. In this study, PRDM8 was found to be down-regulated in HCC, which was linked with shorter recurrence-free survival. Lentiviral-based overexpression and knockdown approaches showed that PRDM8 inhibited HCC cell proliferation, migration, and invasion. PRDM8 caused G1/S cell cycle arrest and induced apoptosis. An in vivo tumor model confirmed the antitumor role of PRDM8 in HCC growth and metastasis. Mechanistic study showed that PRDM8 suppressed the PI3K/AKT/mTOR signaling cascade through the regulation of nucleosome assembly protein 1-like 1 (NAP1L1). Conclusion: PRDM8 as a functional tumor suppressor is frequently down-regulated in HCC. Through regulating NAP1L1, PRDM8 inhibits PI3K/AKT/mTOR signaling in HCC. PRDM8 is a potential target for therapies of HCC. (Hepatology 2018).
引用
收藏
页码:994 / 1009
页数:16
相关论文
共 50 条
  • [21] Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma
    Liu, Chunxiao
    Zhou, Chenhao
    Xia, Weiya
    Zhou, Yifan
    Qiu, Yufan
    Weng, Jialei
    Zhou, Qiang
    Chen, Wanyong
    Wang, Ying-Nai
    Lee, Heng-Huan
    Wang, Shao-Chun
    Kuang, Ming
    Yu, Dihua
    Ren, Ning
    Hung, Mien-Chie
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [22] Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma
    Guo, Rui
    Rao, Pan-guo
    Liao, Bao-zhen
    Luo, Xin
    Yang, Wen-wen
    Lei, Xing-heng
    Ye, Jun-ming
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [23] CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis
    Lv, Shuai
    Li, Yingxia
    Ning, Hanbing
    Zhang, Meihui
    Jia, Qiaoyu
    Wang, Xijuan
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] Targeting endogenous DLK1 exerts antitumor effect on hepatocellular carcinoma through initiating cell differentiation
    Cai, Chun-Miao
    Xiao, Xu
    Wu, Bing-Hao
    Wei, Bao-Feng
    Han, Ze-Guang
    ONCOTARGET, 2016, 7 (44) : 71466 - 71476
  • [25] Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy
    Gong, Yanxia
    Wu, Xiang
    Wang, Tao
    Zhao, Jia
    Liu, Xi
    Yao, Zhi
    Zhang, Qingyu
    Jian, Xu
    ONCOTARGET, 2017, 8 (25) : 40454 - 40468
  • [26] CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis
    Shuai Lv
    Yingxia Li
    Hanbing Ning
    Meihui Zhang
    Qiaoyu Jia
    Xijuan Wang
    Scientific Reports, 11
  • [27] DEAD-box helicase 1 inhibited CD8+ T cell antitumor activity by inducing PD-L1 expression in hepatocellular carcinoma
    Liu, Junhao
    Yang, Ti
    Luo, Yurong
    Ma, Zengxin
    Yu, Zhitao
    Zhang, Lei
    Liu, Gai
    Wen, Jianfan
    Lu, Guankun
    Zhang, Guowei
    Zhao, Yujun
    Luo, Wang
    Li, Yanan
    Yang, Nengjia
    Zhou, Jiawei
    Lu, Yuhui
    Chen, Siliang
    Zeng, Xiancheng
    CANCER SCIENCE, 2024, 115 (03) : 763 - 776
  • [28] PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells
    Qing Li
    Liren Zhang
    Wenhua You
    Jiali Xu
    Jingjing Dai
    Dongxu Hua
    Ruizhi Zhang
    Feifan Yao
    Suiqing Zhou
    Wei Huang
    Yongjiu Dai
    Yu Zhang
    Tasiken Baheti
    Xiaofeng Qian
    Liyong Pu
    Jing Xu
    Yongxiang Xia
    Chuanyong Zhang
    Jinhai Tang
    Xuehao Wang
    Nature Communications, 13
  • [29] PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells
    Li, Qing
    Zhang, Liren
    You, Wenhua
    Xu, Jiali
    Dai, Jingjing
    Hua, Dongxu
    Zhang, Ruizhi
    Yao, Feifan
    Zhou, Suiqing
    Huang, Wei
    Dai, Yongjiu
    Zhang, Yu
    Baheti, Tasiken
    Qian, Xiaofeng
    Pu, Liyong
    Xu, Jing
    Xia, Yongxiang
    Zhang, Chuanyong
    Tang, Jinhai
    Wang, Xuehao
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [30] Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
    Liu, Jianhua
    Liu, Yahui
    Meng, Lingyu
    Liu, Kai
    Ji, Bai
    ONCOLOGY REPORTS, 2017, 38 (02) : 899 - 907